Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer

Kotagiri, Nalinikanth; Cooper, Matthew; Rettig, Michael P.; Egbulefu, Christopher; Prior, Julie L.; Cui, Grace; Karmakar, Partha; Zhou, Mingzhou; Yang, Xiaoxia; Sudlow, Gail; Marsala, Lynne; Chanswangphuwana, Chantiya; Lu, Lan; Habimana-Griffin, Le Moyne; Shokeen, Monica; Xu, Xinming; Weilbaecher, Katherine N.; Tomasson, Michael H.; Lanza, Gregory M.; DiPersio, John F.; Achilefu, Samuel

doi:10.1038/s41467-017-02758-9

Cited by 63 publications

(69 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, many fluorescence imaging agents have been designed for tumor imaging and/or therapy, such as radionuclide, iron nanoparticles, and near-infrared (NIR) agents (Kotagiri et al, 2018;Lu et al, 2018). Among all the imaging agents, indocyanine green (ICG) is the only NIR agent approved for clinical use by Food and Drug Administration (FDA) (Hwang et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Targeting Fluorescence Imaging of RGD-Modified Indocyanine Green Micelles on Gastric Cancer

Shao

Zheng

Feng

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Early diagnosis and complete resection of the tumor is an important way to improve the quality of life of patients with gastric cancer. In recent years, near-infrared (NIR) materials show great potential in fluorescence-based imaging of the tumors. To realize a satisfying intraoperative fluorescence tumor imaging, there are two pre-requirements. One is to obtain a stable agent with a relatively longer circulation time. The second is to make it good biocompatible and specific targeting to the tumor. Here, we developed an RGD-modified Distearyl acylphosphatidyl ethanolamine-polyethylene glycol micelle (DSPE-PEG-RGD) to encapsulate indocyanine green (ICG) for targeting fluorescence imaging of gastric cancer, aimed at realizing tumor-targeted accumulation and NIR imaging. 1 H NMR spectroscopy confirmed its molecular structure. The characteristics and stability results indicated that the DSPE-PEG-RGD@ICG had a relatively uniform size of <200 nm and longer-term fluorescence stability. RGD peptides had a high affinity to integrin α v β 3 and the specific targeting effect on SGC7901 was assessed by confocal microscopy in vitro. Additionally, the results of cytotoxicity and blood compatibility in vitro were consistent with the acute toxicity test in vivo, which revealed good biocompatibility. The biodistribution and tumor targeting image of DSPE-PEG-RGD@ICG were observed by an imaging system in tumor-bearing mice. DSPE-PEG-RGD@ICG demonstrated an improved accumulation in tumors and longer circulation time when compared with free ICG or DSPE-PEG@ICG. In all, DSPE-PEG-RGD@ICG demonstrated ideal properties for tumor target imaging, thus, providing a promising way for the detection and accurate resection of gastric cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting Fluorescence Imaging of RGD-Modified Indocyanine Green Micelles on Gastric Cancer

Shao

Zheng

Feng

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Cherenkov radiation occurs when a particle travels faster than the speed of light through a medium, which is seen with multiple radioisotopes (Shaffer, Pratt, & Grimm, ) (Hoogendam et al, ; Phillips et al, ; Pratt, Shaffer, & Grimm, ). Research shows that Cherenkov radiation from medical radioisotopes can activate photosensitizer to produce ROS (Kotagiri et al, ). Both external‐beam radiation and internal irradiation are widely utilized for cancer treatment, underscoring the clinical relevance and prospects of X‐PDT and CR‐PDT.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles to mediate X‐ray‐induced photodynamic therapy and Cherenkov radiation photodynamic therapy

Cline

Delahunty

Xie

2018

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has emerged as an attractive option for cancer treatment. However, conventional PDT is activated by light that has poor tissue penetration depths, limiting its applicability in the clinic. Recently the idea of using X-ray sources to activate PDT and overcome the shallow penetration issue has garnered significant interest. This can be achieved by external beam irradiation and using a nanoparticle scintillator as transducer. Alternatively, research on exploiting Cherenkov radiation from radioisotopes to activate PDT has also begun to flourish. In either approach, the most auspicious success is achieved using nanoparticles as either a scintillator or a photosensitizer to mediate energy transfer and radical production. Both X-ray induced PDT (X-PDT) and Cherenkov radiation PDT (CR-PDT) contain a significant radiation therapy (RT) component and are essentially PDT and RT combination. Unlike the conventional combination, however, in X-PDT and CR-PDT, one energy source simultaneously activates both processes, making the combination always in synchronism and the synergy potential maximized. While still in early stage of development, X-PDT and CR-PDT address important issues in the clinic and hold great potential in translation. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

show abstract

“…[38,46] CD146-targeted RIT will hopefully lead to tumor-specific lethal DNA damage and enhanced immune responses. Although studies have shown that Cerenkov radiation from beta emitters (such as 64 Cu and 18 F) can be used to excite photosensitizers (such as TiO 2 nanoparticles) to realize deep-tissue PDT, [48,49] future studies are needed Adv. Although studies have shown that Cerenkov radiation from beta emitters (such as 64 Cu and 18 F) can be used to excite photosensitizers (such as TiO 2 nanoparticles) to realize deep-tissue PDT, [48,49] future studies are needed Adv.…”

Section: Discussionmentioning

confidence: 99%

CD146‐Targeted Multimodal Image‐Guided Photoimmunotherapy of Melanoma

et al. 2019

View full text Add to dashboard Cite

For melanoma resistant to molecularly targeted therapy and immunotherapy, new treatment strategies are urgently needed. A molecularly targeted theranostic pair may thus be of importance, where the diagnostic probe facilitates patient stratification and the therapeutic companion treats the selected cases. For this purpose, flow cytometry is used to assess the CD146 level in melanoma cells. Based on YY146, a CD146‐specific monoclonal antibody, an imaging probe 89 Zr‐Df‐YY146 is synthesized and its diagnostic performance is evaluated by positron emission tomography (PET) imaging. Furthermore, a photoimmunotherapy (PIT) agent IR700‐YY146 is developed and the therapeutic effect of IR700‐YY146 PIT is assessed comprehensively. CD146 is highly expressed in A375 and SK‐MEL‐5 cells. 89 Zr‐Df‐YY146 PET readily detects CD146‐positive A375 melanomas. Tumor accumulation of 89 Zr‐Df‐YY146 peaks at 72 h with an uptake value of 26.48 ± 3.28%ID g −1 , whereas the highest uptake of the nonspecific 89 Zr‐Df‐IgG is 4.80 ± 1.75%ID g −1 . More importantly, IR700‐YY146 PIT effectively inhibits the growth of A375 tumors, owing to production of reactive oxygen species, decreased glucose metabolism, and reduced expression of CD146. To conclude, 89 Zr‐Df‐YY146 and IR700‐YY146 are a promising theranostic pair with the former revealing CD146 expression in melanoma as a PET probe and the latter specifically treating CD146‐positive melanoma as an effective PIT agent.

show abstract

Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer

Cited by 63 publications

References 37 publications

Targeting Fluorescence Imaging of RGD-Modified Indocyanine Green Micelles on Gastric Cancer

Targeting Fluorescence Imaging of RGD-Modified Indocyanine Green Micelles on Gastric Cancer

Nanoparticles to mediate X‐ray‐induced photodynamic therapy and Cherenkov radiation photodynamic therapy

CD146‐Targeted Multimodal Image‐Guided Photoimmunotherapy of Melanoma

Contact Info

Product

Resources

About